OKT-3/cyclophosphamide up-regulation of peripheral blood killer-lymphocyte subsets in human cancer patients.
We have initiated a clinical trial in 7 patients using low-dose OKT-3 monoclonal antibody, 50 mcg, followed 24 hours later by low-dose cyclophosphamide, 300 mg/m2. Complete data in 5 patients indicate a significant up-regulation of the number of peripheral blood lymphocytes. Before treatment, the mean (+/- standard deviation) total lymphocyte count was 524 (+/- 364)/mm3. After 4 weeks the value rose 64% to 860 (+/- 243)/mm3, (P less than .025, Student's t test). Similar changes were observed for the CD3+, CD4+, CD8+, and CD16+ (NK) lymphocyte subsets. The mean CD3+ population rose from 372 (+/- 325)/mm3 to 593 (+/- 300)/mm3 (P less than .025), the mean CD4+ group rose from 209 (+/- 142)/mm3 to 321 (+/- 104)/mm3 (P less than .05), the CD8+ cells rose from 218 (+/- 205)/mm3 to 341 (+/- 197)/mm3 (P less than .05), and the CD16+ (NK cells) rose from 80 (+/- 37)/mm3 to 157 (+/- 63)/mm3 (P less than .025). Statistically significant up-regulation occurred for all patients. The fraction of each lymphocyte subset and the T4/T8 ratio did not change. OKT-3/cyclophosphamide appears to modulate the number of circulating lymphocytes in human cancer patients.
Wiseman
C
C
Wilshire Oncology Medical Group, St. Vincent Medical Center, Los Angeles CA 90057.
Hood
Y
Y
Presant
C
C
Kennedy
P
P
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D015703:Antigens, CD / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D017252:CD3 Complex; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000473:pathology; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000473:pathology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D011948:Receptors, Antigen, T-Cell; D003520:Cyclophosphamide